TrialInvestigational new drugs2012

Multicenter phase II study of S-1 monotherapy as second-line chemotherapy for advanced biliary tract cancer refractory to gemcitabine.

Takashi Sasaki et al.PubMed ↗Publisher ↗

No numbers read from the abstract.